Cited by — FDA Approval Summary: Epcoritamab with Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma | ResearchHub - ResearchHub
Research graph
Cited by
Admitted local publications that cite FDA Approval Summary: Epcoritamab with Lenalidomide and Rituximab for Relapsed or Refractory Follicular Lymphoma.
No admitted local citation edges point to this work yet.
